Disease burden and direct medical costs of incident adult ADHD: A retrospective longitudinal analysis based on German statutory health insurance claims data.
Berit LibutzkiMelanie MayMarkus GleitzMichael KarusBenno NeukirchCatharina A HartmanAndreas ReifPublished in: European psychiatry : the journal of the Association of European Psychiatrists (2020)
We conclude that earlier recognition of aADHD could prevent the development and aggravation of comorbid mental illnesses. At the same time, comorbid conditions may have masked ("over-shadowed") aADHD and delayed diagnosis. The burden of disease in aADHD is high, which was noticeable especially among individuals who received initial ADHD-medication, suggesting that psychopharmacological treatment was mainly considered for the most severely ill. We conclude that measures to facilitate access of aADHD patients to clinical experts are required to improve reality of care in the outpatient setting.
Keyphrases
- health insurance
- affordable care act
- attention deficit hyperactivity disorder
- healthcare
- autism spectrum disorder
- end stage renal disease
- ejection fraction
- working memory
- newly diagnosed
- chronic kidney disease
- cardiovascular disease
- prognostic factors
- palliative care
- mental health
- quality improvement
- machine learning
- artificial intelligence
- deep learning
- chronic pain
- data analysis
- adverse drug
- replacement therapy
- patient reported